Status:

COMPLETED

Efficacy and Safety of GENOSS® DES in Patients with Coronary Artery Disease

Lead Sponsor:

Genoss Co., Ltd.

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

19+ years

Brief Summary

The objective of this study is to evaluate the efficacy and safety of the GENOSS DES in patients with coronary artery disease in real-world pratice.

Detailed Description

The Genoss DES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. Although the efficacy and safety of this stent have been previou...

Eligibility Criteria

Inclusion

  • \<Inclusion Criteria\>
  • Patients of 19 and over
  • Patients eligible for treatment of coronary artery disease using GENOSSTM DES
  • Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as research participants.
  • \<Exclusion Criteria\>
  • Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents (However, patients with hypersensitivity to contrast agents may be eligible if it can be controlled by steroids and pheniramine. Patients with known anaphylaxis are excluded)
  • Patients who are pregnant or planning to become pregnant
  • Patients scheduled to undergo surgery requiring the discontinuation of antiplatelet agents within 12 months from registration
  • Patients with a life expectancy of less than 1 year
  • Patients who presented with cardiogenic shock at admission and are predicted to have a low chance of survival based on medical judgment
  • Patients who have already received treatment with another DES (Drug Eluting Stent), BVS (Bioresorbable Vascular Scaffolds), or BMS (Bare Metal Stent) at the time of registration
  • Patients currently participating in a randomized controlled trial involving medical devices

Exclusion

    Key Trial Info

    Start Date :

    June 24 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    October 31 2024

    Estimated Enrollment :

    1022 Patients enrolled

    Trial Details

    Trial ID

    NCT06066476

    Start Date

    June 24 2017

    End Date

    October 31 2024

    Last Update

    February 20 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Korea University Guro Hospital

    Seoul, South Korea, 08308